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The Role Of Ultrasonography To Evaluate Chest Wall Sarcomas
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Objectives: Surgery  is  the  elective  treatment  for  chest  wall
sarcoma. Local recurrence, varies from 7%  (Pairolero) to  52%
(King), and  is  normally  determined by  an  inadequate  surgical
exeresis.
The goal of this paper is to de￿ ne a preoperative approach to study
tumor margins.
Methods: 19 patients with a chest wall sarcoma were routinely
submitted to an Rx, CT, MRI, total body scintigraphy, and US
evaluation. US was always performed by the same person with a
Siemens  Sonoline  Omnia, employing  a  probe  5–13  Mhz, and
performing a color-doppler evaluation of the lesion.The scan was
done with the patient lying in the surgical position.Tumor lateral
margins were identi￿ ed and a line was marked out at 4 cm (safe
oncological margin).
Results: Histologically  all  the  surgical  specimen  removed
following the US margins revealed wide exeresis (Enneking classi-
￿ cation).On the contrary CT scan and MRI showed a 27% under-
estimation and a 18% overestimation respectively of the tumor
lateral  margins. CT  and  MRI  correctly  evaluated  in  94%  of
patients deep margins.
US detected one or more micronodules in 4 out of 5 patients with
local  recurrence. Histologically  they  were  all  sarcoma  nodules
(mean diameter 3 mm).
18 patients were disease free at 24 months (4–9). One patient died
due to cerebral and bone metastasis.
Conclusions: US sensitivity (100%), speci￿ city (98%), and accu-
racy (98%) in detecting chest wall involvement of lung cancer is
well known since 10 years (Suzuki). Our results con￿ rm the reli-
ability of US also in the study of chest wall sarcomas super￿ cial
margins and micronodules.
High-resolution Intravascular Ultrasonography To Assess Vessel-
invasiveness Of Soft Tissue Sarcoma
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Objectives: Detecting the extension of local spread of soft tissue
sarcoma (STS) is of utmost importance for adequate resection.
However, even MRI fails in correctly describing tumor invasion to
neurovascular  bundles. We  explored, whether  high-resolution
(intravascular ultrasound (IVUS) improves correct assessment of
vascular in￿ ltration.
Methods: To qualify for enrollment, patients had to have a histo-
logically  con￿ rmed  STS  with  the  tumor  located  close  to  and
suspected to invade a neurovascular bundle.
Twenty-eight patients (12 f, 16 m, age 30–72 yrs) were examined.
Tumors were located in the retroperitoneum (n=4), groin (n=7),
thigh  (n=9), popliteal  fossa  (n=9), lower  leg  (n=2), and  axilla
(n=1).Typing: liposarcoma (n=8), leiomyos. (n=6), MFH (n=6),
synovial (n=5), MPNST (n=3), alveolar (n=1), hemangiopericy-
toma (n=1).
A 2.9F IVUS-catheter (12.5 MHz, Ultracross, Boston Scienti￿ c
Corp.) was inserted via a side branch of the vessels exposed distant
to the tumor during resection. IVUS ￿ ndings were compared with
intraoperative assessment and the resection specimen.
Results: In 16 patients, the vessels were resected, while 2 patients
underwent subadventitial dissection, and in 10 patients the vessels
were left untouched. IVUS detected 13 cases of vessel-invasive
sarcoma (true positives). There were two false positives and one
false negative whereas in another 12 cases no invasion could be
found (true negative). Sensitivity:92.8%, Speci￿ city: 85.7%,posi-
tive  predictive  value  (PPV): 86.6%, negative  predictive  value
(NPV): 92.3%.
Conclusions: IVUS provides an excellent tool to assess vessel inva-
sion of STS. It can be handled intraoperatively and by this way
allows the surgeon to examine the region of interest exactly. High-
resolution ultrasound might overcome some of the problems of
local staging still being not solved by MRI.
Predictive Value Of Gadolinium Enhancement In Differentiating
Atypical Lipomas (well-differentiated Liposarcomas) From Benign
Fatty Tumors
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Objectives: To  determine  the  predictive  value  of  gadolinium
enhancement on  MRI in differentiating atypical  lipomas  (well-
differentiated liposarcomas) from benign fatty tumors.
Methods: Of 129 patients evaluated in the of￿ ce of the senior
author for fatty tumors over the period 1994–2002, the patient
population was narrowed to 34 histologically proven fatty tumors
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(In Program order)with pre-op gadolinium-enhanced MRI, 14 of whom had under-
gone  biopsy  after the  MRI. Pre-operative gadolinium  enhance-
ment was based upon consensus of the musculoskeletal surgeon
and  radiologists prior  to  de￿ nitive  operation. Sensitivity, speci-
￿ city, positive and negative predictive values for both gadolinium
enhancement and biopsy in predicting ￿ nal atypical lipoma diag-
nosis  (considered equivalent  to  well-differentiated liposarcoma)
were calculated.
Results: As a predictor of atypical lipoma, gadolinium enhance-
ment showed 100% sensitivity , 71% speci￿ city , 59% positive
predictive value, and 100% negative predictive value. Needle or
incisional biopsy yielded 67% sensitivity, 100% speci￿ city , 100%
positive predictive value, and 63% negative predictive value.
Conclusions: Gadolinium  enhancement  of  a  homogenous  fatty
soft tissue tumor, when determined by consensus of an experi-
enced musculoskeletal team, is a sensitive screening tool to deter-
mine possible diagnosis of atypical lipoma. Biopsy, on the other
hand,is speci￿ c but insensitive.An algorithm is proposed for eval-
uation of these tumors in which all deep or large tumors undergo
screening with gadolinium-enhanced MRI.Only those tumors that
enhance would be considered for directed biopsy.
Fdg-  Positron  Emission  Tomography  (pet)  In  Staging  And
Managing Patients With Soft Tissue Sarcomas
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Objectives: FDG (2–18￿ uoro-2-deoxy-D-glucose) PET scanning
is useful for oncologic staging and treatment assessment.We eval-
uated its role in patients with soft tissue sarcomas.
Methods: 59  patients  underwent  97  PET  scans, 50  at  initial
staging, which included primary site MRI and chest CT. PET
activity was scored as 0=normal,1= minimal,2=moderate,and 3=
intense. PET results were compared with chest CT to assess sensi-
tivity /speci￿ city. Most patients underwent neoadjuvant radiation
or chemoradiation followed 3–4 weeks later by surgery. Re-staging
PET, MRI, and chest CT were performed 1–3 weeks after neoad-
juvant therapy and PET activity in the primary site was correlated
to residual tumor in the surgical specimen.
Results: Increased activity  was  seen  at  the  primary  site  in  47
patients (94 %);median and mean activity scores were respectively
3  and 2.75. Two patients without PET activity had undergone
excisional biopsy; a third had grade 1 liposarcoma. Sensitivity and
speci￿ city for PET for detecting lung metastases were 0.09 and
0.97 respectively,compared to 0.75 and 0.83 for chest CT.Positive
and  negative  predictive  values  for  PET  were  0.50  and  0.77
compared to 0.56 and 0.92 for chest CT. On 39 re-staging PETs
after neoadjuvant treatment, there was less activity, median score
2 and mean 2.18. No clear relationship emerged between residual
activity and percent necrosis in the surgical specimen, although
this has not yet been corrected for tumor grade.
Conclusions: Soft tissue sarcomas are FDG avid at the primary
site; activity decreases with neoadjuvant therapy. PET scanning is
not useful for detection of lung metastases.
Fluorodeoxyglucose  Uptake  In  Adult  Soft  Tissue  Sarcoma
Predicts Risk Of Recurrence After Chemotherapy
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Objectives: Patients with localized, high-grade soft tissue sarco-
mas (STS) are at signi￿ cant risk of developing metastasis.Chemo-
therapy may reduce the risk of relapse; however, not all patients
bene￿ t  from  treatment. High-grade  STS  metabolize  ￿ uorode-
oxyglucose (FDG) to a greater extent than normal tissue which can
be quanti￿ ed by positron emission tomography (PET).We sought
to determine whether the change in metabolic activity of STS in
response to chemotherapy could serve as a surrogate measure for
chemosensitivity and correlate with risk of disease recurrence.
Methods: FDG-PET was performed prior to doxorubicin-based
chemotherapy and prior to surgery. Patients were followed for a
minimum of 2 years for recurrence of disease and death. Patient
outcomes were analyzed by Kaplan-Meier analyses strati￿ ed by
change in FDG uptake, tumor grade, tumor size and pathologic
response.
Results: Thirty-eight  patients  with  localized, high-grade  STS
were retrospectively studied. Seventeen patients  remain  free of
tumor with a median follow-up of 3 years. Patients with a greater
than 40% decrement in the maximum  FDG uptake in STS in
response to chemotherapy had a signi￿ cantly lower risk of relapse
and improved survival.Risk of relapse did not correlate with tumor
grade, size or pathologic response to therapy.
Conclusions: A change in the metabolism of FDG in response to
chemotherapy may serve as a surrogate measure of chemotherapy
sensitivity in high-grade soft tissue sarcomas. Patients with a large
decrement in FDG uptake in response to doxorubicin-based ther-
apy have a lower risk of disease recurrence and improved survival.
Should Soft Tissue Sarcomas Be Treated At A Specialist Centre?
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Objectives: We have investigated whether there is evidence that
patients with soft tissue sarcomas do better if treated in a specialist
centre compared with district general hospitals.
Methods: We analysed the outcomes for all patients with soft tis-
sue sarcomas in one health region of the UK over a 3 year period,
with minimum follow up of 5 years.We have investigated appropri-
S64 Ashford et al.ateness of treatment, adequacy of surgery, and outcomes in terms
of local control and overall survival.Results are strati￿ ed for known
risk factors for local control and survival (grade, depth and size).
Results: 260 patients were diagnosed as having STS over the 3
year period of whom 37% had the majority of treatment at the
specialist centre under the care of 2 surgeons,whilst the other 63%
were treated at a total of 38 different hospitals. Local recurrence
rates were 20% at the specialist centre and 37% at the general
hospitals. Overall survival was 58% at ￿ ve years and was related to
grade, depth and size of tumour. Patients treated at the specialist
centre had larger tumours (10.3 vs 7.3cm) with a higher propor-
tion of deep and high grade tumours. Overall survival at the two
centres was identical but when strati￿ ed for known risk factors the
survival rate was 1.6 times better at the specialist centre,this differ-
ence being especially obvious for Stage III tumours (p = 0.009).
Conclusions: Soft tissue sarcomas are rare.Centralization of treat-
ment, especially for high grade tumours improves survival, local
control and patients care.
Positive Margins After Attempted Wide Excision Of A Soft Tissue
Sarcoma: Is Further Excision Necessary?
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Objectives: When the surgical margin is positive after a planned
wide excision,the aims of our study were to discern:1)Is additional
surgical excision or amputation warranted and, 2)If no additional
surgery is done, is there a difference in overall survival (OS), con-
tinuous disease free survival (CDFS) or local recurrence (LRFS)?
Methods: We performed a review of all patients meeting the inclu-
sion  criteria: non-metastatic  soft  tissue  sarcomas  (excluding
rhabdo),extremity,trunk,retroperitoneum,treatment period 1975
– 1997 @ Univ.Minnesota,age > 13 years.The treatment protocol
was: attempted  wide  local  excision, adjuvant  radiation  when
closest margin is marginal, if positive margin identi￿ ed on patho-
logical analysis, further excision considered if technically possible
depending upon size of surgical bed, anatomic location, patient’s
desires. Independent pathologist evaluation was performed with
surgical margins de￿ ned as: Negative (> 2 mm closest margin),
Negative (< 2 mm closest margin), Positive-microscopic, Positive-
macroscopic (gross tumor remaining), Inadvertent intraop conta-
mination. Patients w/ a positive margin were then compared to
those w/ a negative margin using standard survivorship analysis
and Cox stepwise regression statistical methods.
Results: The study cohort consisted of 413 patients (180 female,
233 male), mean age 51 yrs, with diagnoses liposarcoma (104),
MFH (142), synovial sarcoma (44), other sarcoma (123).Tumor
grades were low (50), intermediate(53), & high (254). External
beam radiation, mean dose 5688 cGy, was given preoperatively w/
postop boost to 112 (27%)patients & postoperatively only to 170
(41%) patients. No radiation was given to 131 (32%) patients.
There was no difference in 5 yr OS between the positive vs. nega-
tive margin group, 76% vs. 61% (p=0.4), respectively.There was
no  difference in  5  yr  CDFS  between  the  positive  vs. negative
margin group, 61% vs. 68% (p=0.21), respectively. There was a
statistical difference in 5 yr LRFS with the negative margin group
being higher, 88% vs. 75% (p=0.02).The in￿ uence of grade and
margin revealed that for LRFS, positive margin was a risk factor
(p=0.02) but grade was not. For both CDFS and OS, grade was
a risk factor (p=0.01 and 0.04, respectively) but margin status was
not.Among only low grade tumors there was no diff in OS, CDFS
or  LRFS  comparing  the  positive  vs. negative  margin  groups.
Among  only  high  grade  tumors, there  was  a  diff  in  LRFS
(p=0.002) and CDFS (p=0.049) but not OS.
Conclusions: We conclude a positive margin is associated with a
higher risk of local relapse but not necessarily survival.When a pos-
itive surgical margin is sustained after a planned attempt at wide
excision,additional surgery is not warranted for low grade tumors.
For high grade tumors, CDFS but not OS is shorter when a posi-
tive margin occurs and therefore,it is uncertain if this is signi￿ cant
enough to warrant additional ablative surgery or amputation.
Microarray Analysis Of Malignant Fibrous Histiocytoma
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Objectives: Malignant  ￿ brous histiocytoma (MFH) is the most
common type of  soft  tissue sarcoma but  is poorly  understood.
There are few accurate predictors of outcome to guide treatment
decisions.We used microarray analysis of gene expression to iden-
tify prognostic markers for MFH.
Methods: 40  MFH  tumor  specimens  with  clinical  data  were
chosen from a prospective tumor bank from patients who did not
receive preoperative chemotherapy or radiotherapy. Frozen speci-
mens were assessed histologically to con￿ rm viable tumor.Tumor
and control RNA were indirectly labelled with ￿ uorescent tags and
simultaneously hybridized to 19K microarray slides. Arrays were
scanned, quantitated and normalized prior to statistical analysis
using GenePix and SPlus,and then analysed with BrB ArrayTools.
Results: We selected 111 “candidate” genes from a variety of bio-
logical pathways with potential importance in MFH,and examined
their ability to discriminate between clinicopathologic variables,
stage, and oncologic outcome. For each clinical variable, a group
of 5–13 genes were identi￿ ed which distinguished between cate-
gorical strata (F-test p<0.05).For example,10 genes differentiated
between patients who did or did not develop metastases,including
TOK1 (p21-binding protein),SEI1 (cdk4-binding protein),CA1A
(collagen-related gene), IRF1 (interferon regulatory factor1) and
MMP9. However, rigorous assessment of prediction error using
cross-validation  techniques suggested  that  combinations  of  the
above genes did not signi￿ cantly improve prediction, recognizing
the low power and small size of this sample.
Conclusions: This  study  suggests  that  the  candidate  gene  list
approach  does not provide the most accurate method for class
CTOS abstracts S65prediction for MFH.We are presently undertaking tumor compar-
ison using an expanded microarray 19K gene set without prede-
termined  gene  selection  which  will  likely  be  a  more  powerful
approach to identify prognostically important genes in MFH.
Genome-wide Analysis Of Gene Expression In Synovial Sarcoma
Using A Cdna Microarray
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Objectives: Among soft tissue sarcomas, synovial sarcoma (SS) is
regarded as a miscellaneous entity of uncertain origin. Although
the presence of SYT-SSX fusion gene is a hallmark of this type of
tumor, its genetic features remain largely unclear.
Methods: We examined genome-wide gene expression pro￿ les of
13 SS cases and 34 other spindle cell sarcoma cases, including
MFH, leiomyosarcoma (LMS), pleomorphic or dedifferentiated
liposarcoma (PLS or DLS),and malignant peripheral nerve sheath
tumor (MPNST), by means of cDNA microarray consisting of
23,040 genes.
Results: A hierarchical clustering analysis using the data of 1,204
genes revealed that MFH, LMS,PLS,and DLS failed to compose
a disease-speci￿ c cluster. On the other hand, SS cases showed a
distinct cluster along with MPNST. Four biphasic tumors were
clustered  closely  together, whereas  tumors  with  monophasic
features failed to make one cluster. 26 genes were identi￿ ed as
genes that were commonly upregulated in SS, of which most were
also upregulated in MPNST, and the presumed function of known
genes among them were related to migration or differentiation of
neural crest cells, a  strong  indication  that  SS  originates in  the
neuroectoderm. On  the basis  of  the expression  patterns of  the
1,405  genes, 13  SS  tumors  were subdivided  into  two  distinct
subclasses. 15 additional  SS  cases were also successfully subdi-
vided into either of two groups, suggesting the novel subclassi￿ ca-
tion of SS based on the gene expression pro￿ les.
Conclusions: These data provide us with the information for the
origin of SS, and also several candidate genes for molecular ther-
apeutic targets.
Differential Gene Expression In Leiomyosarcoma.
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Objectives: Soft  tissue sarcomas  are  a  heterogeneous group  of
malignancies  of  mesenchymal  origin, the  causes  of  which  are
unclear. In  this  study  gene  expression  in  leiomyosarcomas,
myometrium, and uterine leiomyomas was examined.
Methods: RNA  was  prepared  and  gene  expression  was  deter-
mined at Gene Logic Inc. (Gaithersburg, MD) using Affymetrix
GeneChip® U_95 arrays containing approximately 12,000 known
genes and 48,000 ESTs. Gene expression analysis was performed
with Gene Logic Gene Express® software. Differences in gene
expression were quanti￿ ed as the fold change in gene expression
in  leiomyosarcomas  compared  with  normal  myometrium, and
uterine leiomyomas.
Results: A number of genes were differentially expressed in these
sample sets, and these genes were analyzed for their expression in
a variety of other normal and diseased tissues. Some of the genes
identi￿ ed were over-expressed only in leiomyosarcomas among the
tissues examined, and some were over-expressed in other tissues
as well
Conclusions: We conclude that differences in gene expression can
be detected between leiomyosarcomas and uterine leiomyomas,
and normal myometrium, and that these changes in gene expres-
sion may yield clues to the pathophysiology of this malignancy.
Antisense  Inhibition  Of  Hyaluronan  Synthase-2  In  Human
Osteosarcoma Cell Line, Mg-63, Inhibits Hyaluronan Retention
And Tumorigenicity Of The Cells
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Objectives: Osteosarcoma  is  the  common  primary  malignant
tumor  of  bone  and is  represented by  a  heterogenous group  of
lesions  with  diverse  histopathology  and  clinical  behavior.
Hyaluronan (HA) has been thought  to play  signi￿ cant roles in
tumor progression. The aim of this study was to determine the
differential pattern  of  expression  of  three  hyaluronan  synthase
genes  (HAS), that  are  responsible  for  the  synthesis  of  HA  in
osteosarcomas.An additional goal was to analyze the effects of the
inhibition of HAS genes by means of antisense oligonucleotides on
the behavior of osteosarcoma cells.
Methods: Total RNA was isolated from osteosarcoma cell lines,
MG-63, which  were  cultured  in  monolayer, and  subjected  to
competitive, quantitative RT-PCR to determine the mRNA copy
numbers of HAS genes. Antisense oligonucleotides complimen-
tary to the predominant HAS gene was transfected into osteosar-
coma cells using a lipofection facilitator. The inhibition of HAS
S66 CTOS abstractsand HA expression was determined competitive RT-PCR and HA
staining,respectively.Cell proliferation and invasion were analyzed
by MTT assay and matrigel assay.
Results: HAS-2  mRNA  expression  was  90-hold  higher  than
HAS-3. Antisense oligos treatment for HAS-2 resulted in a 60%
inhibition of HAS-2 mRNA levels and a remarkable decrease of
HA accumulation around the cells.The suppression of HAS-2 also
lead to the suppression of cell proliferation and invasion.
Conclusions: HA inhibition via the down-regulation of HAS genes
could control the behavior of osteosarcoma cells.Thus, the use of
small antisense oligonucleotides to affect the selective inhibition of
genes may provide a useful tool for the control of osteosarcomas.
Neoplastic Transformation Of Primary Human Osteoblasts Over-
expressing The Met Receptor By Means Of Transduction With
Lentiviral Vectors
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Objectives: The MET oncogene is activated in cell lines where it
is  ampli￿ ed  and  over-expressed. Point  mutations  of  its  kinase
domain  leading  to  its  activation  have  been  found  in  families
suffering from hereditary papillary renal cell carcinomas.We previ-
ously showed that the receptor is aberrantly expressed in a number
of  human  osteosarcomas producing  the  ligand, suggesting  that
overexpression of MET receptor(s) might contribute to transfor-
mation of osteoprogenitor cells.
Methods: To demonstrate the transforming potential of MET in
human osteoblast-like cells(HOB-L), we constructed an ex-vivo
model using primary cultures of HOB-L stably expressing wild-
type or constitutively-active MET receptors by means of trans-
duction with Lentiviral vectors in vitro.
Results: All the wt- and mutant-MET-HOB-L clones showed a
different morphology from parental HOB-L cells, namely a loss of
contact-inhibition, proliferation at low serum concentrations and
anchorage-independent growth.They formed colonies in soft agar,
while the parental HOB-L cells did not.
Tumorigenic  potential  of  MET-HOB-L  cells  was  assayed  in
immuno-compromised SCID mice. Two out 12 animals, which
received wt-MET transduced osteoblast  cells, developed tumor
after a long latency. Nine out of 16 mice receiving mutated MET-
expressing osteoblast cells developed tumors in a shorter period.
These tumors showed features of highly aggressive and undiffer-
entiated osteosarcomas and carried integrated copies of the human
MET.
Conclusions: Over-expression  of  the  MET  oncogene  activated 
by a point mutation makes the same cells not only transformed 
but  also  highly  tumorigenic  in  immuno-compromised  mice.
These results show that over-expression of an activated tyrosine
kinase suf￿ ces to convert a primary human cell into a tumorigenic
cell.
Young Investigator Award Winner
Targeting  Met Oncogene In Human Osteosarcoma  By  K-252a
Tyrosine-kinase Inhibitor: A New Therapeutic Approach
[Abstract ID: 71]
Category: Biology
Presentation:Young Investigator
Authors: So￿ a Avnet
1, Francesca  Perut
1, Riccardo  Ferracini
2,
Maria Flavia Di Renzo
2, Nicola Baldini
1
Author  Institutions: 1Laboratory  of  Pathophysiology  Istituto
Ortopedico Rizzoli Bologna,Italy;
2Laboratory of Cancer Genetics
Institute for Cancer Research and Treatment Candiolo, Italy
Presenter: So￿ a Avnet
so￿ a.avnet@ior.it
Correspondent: Nicola Baldini
nicola.baldini@ior.it
Bologna Italy 40136
Ph: +39.(0)50.6366678
Fax: +39.(0)50.6366748
Objectives: Activation  of  Met, the  tyrosine  kinase  receptor for
HGF/SF, induces downstream signalling pathways that trigger a
number of cell functions, including proliferation, motility, inva-
siveness, and metastatic ability in a variety of neoplasms. Met is
overexpressed in osteosarcoma, in association with an aggressive
behavior of this tumor, both in vitro and in a clinical setting.We
evaluated the ability of a natural alkaloid (K252a) which acts as a
kinase inhibitor, by competing with the binding  of ATP to the
catalitic domain of Met, to interfere with the growth of human
osteosarcoma cells, as a preliminary step toward the development
of innovative therapeutic strategies for this tumor.
Methods: We evaluated the level of Met expression by Western
blotting in human osteosarcoma cell lines (U-2 OS,MG-63,Saos-
2), that are representative of different levels of differentiation and
aggressiveness of osteosarcoma. IC50 was  analyzed at different
concentrations of K252a (50–2000 ng/ml).
Results: In osteosarcoma cells, the level of Met expression was
associated with the ability of K252a to inhibit cell growth. In fact,
the IC50 of K252a was 420 ng/ml in Saos-2, the more differenti-
ated cell line with the lowest expression of Met,whereas it was 55.8
ng/ml in U-2 OS,the cell line with the lowest differentiated pheno-
type and the highest Met levels. Intermediate values (IC50, 190.7
ng/ml) were found in MG63.
Conclusions: K252a  is  a  potent  inhibitor  of  proliferation  of
human osteosarcoma, and its effects are positively associated with
the level of expression of Met, but inversely related to the differ-
entiative status of the tumor.
Differential  Effects  Of  The  Radioprotectant  Amifostine  On
Ewing’s Sarcoma And Human Monocytes In Culture
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Objectives: Radioprotectants must be selectively radioprotectant,
protecting  normal  cells  at  the  expense  of  tumor  cells. Such
selectivity has not been established for sarcomas.The hypothesis
CTOS abstracts S67investigated in this pilot was that amifostine alone would not pro-
mote proliferation of Ewing’s sarcoma cells or human monocytes.
Methods: Amifostine  at  concentrations of  0, 0.5, 1, 2, 5, and 
10 mM was administered to con￿ uent TC-71 Ewing’s sarcoma
cells. At 6, 12, 24, and 72 hours following amifostine administra-
tion, MTT  assays  of  cellular  proliferation  were  performed.
Clonogenicity assays of  reproductive survival were also accom-
plished utilizing 0, 1, 5, and 10 mM concentrations of amifostine.
Human  monocytes  were cultured from  proximal  femoral bone
marrow aspirated during routine total hip  procedures following
IRB approved patient consent. These monocytes were similarly
assayed following amifostine administration ANOVA was utilized
with alpha 0.05.
Results: Amifostine was acutely toxic to TC-71 Ewing’s sarcoma
cells at 5–10 mM, moderately toxic at 2 mM, and mild to moder-
ately toxic at 0.5 and 1 mM as manifested by the MTT assays.
Clonogenicity assays on the amifostine treated TC-71 cells con-
￿ rmed the observations made with the MTT assay. By contrast,
human monocytes exhibited a consistent increase in proliferation
following amifostine administration.
Conclusions: Amifostine  has  a  cytotoxic  effect on  this  Ewing’s
sarcoma cell line at clinically relevant concentrations (1–2 mM).
By contrast,a proliferative effect of amifostine was observed in our
human monocyte culture.These effects are promising and warrant
further study of the putative differential radioprotective properties
of amifostine in sarcomas.
A  Randomized Trial  Of  Amifostine With  High-dose  Alkylator
Therapy In Ewing Sarcoma: A Children’s Oncology Group Trial
(p9457)
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Objectives: To determine if amifostine given twice with each dose
of ifosfamide or cyclophosphamide could provide protection from
the myelotoxic effects of high dosage alkylator therapy,and prevent
delay in the administration of chemotherapy.
Methods: Patients (pts) less than 30 years of age with Ewing sar-
coma  metastatic  at  diagnosis  and  normal  organ  function  were
enrolled on a study of maximally intensi￿ ed alkylator therapy with-
out stem cell support. Cycles included alternating courses of ifos-
famide (3.6 g/m2/day,for 5 days, week 6, then 2.8 g/m2/day,for 5
days,weeks 12 and 18),with etoposide (100 mg/m2/day,for 5 days)
and vincristine (2 mg/m2),doxorubicin (75 mg/m2 over 48 hours)
and cyclophosphamide (2.1 g/m2/day,for 2 days, weeks 9 and 15).
Seventy pts were randomized to receive (36 pts), or not to receive
(34 pts) amifostine. Topotecan(0.75 mg/m2/day,for 5 days) and
cyclophosphamide (250 mg/m2/day,for 5 days) were administered
to 23 patients on the amifostine arm (weeks 0, 3)and 16 on the no
amifostine  arm. The  amifostine  dosage  administered  was  825
mg/m2 15 minutes prior to,and 3 hours after the beginning of each
dose of ifosfamide or cyclophosphamide,with premedications and
precautions as previously described. Days ANC < 500/ul, days
platelets < 50,000/ul and days between cycles were analyzed at
weeks 6, 12 and 18 of therapy.
Results: There was no signi￿ cant difference seen in any of the
parameters studied: the mean number of days with platelet count
< 50,000/ul:Wilcoxon rank sum test (WRS test,p-value:0.29),the
mean number of days with absolute neutrophil count < 500/ul:
(WRS, p = 0.15), or the number of days until the next chemo-
therapy  cycle: (p=  0.42). Toxicities  attributable  to  amifostine
included increased emesis, reversible hypotension, and asympto-
matic hypocalcemia responding to calcium supplementation.
Conclusions: In the dose and schedule used, amifostine did not
provide myeloprotection from the toxicity of high dose alkylator
therapy, and did not shorten the interval until the
administration of the next chemotherapy cycle.
Randomised Phase 3 Trial Of Two Investigational Schedules Of
Ifosfamide Versus Standard Dose Doxorubicin In Patients With
Advanced Or Metastatic Soft Tissue Sarcoma (asts).
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Objectives: Doxorubicin and ifosfamide show signi￿ cant activity
in soft tissue sarcoma but have never been formally compared.We
report a randomised Phase III comparison of single agent doxoru-
bicin 75mg/m2 versus ifosfamide 3g/m2 over 4 hours daily for 3
days (Ifos 3*3) versus ifosfamide 9g/m2 over 72 hours by contin-
uous infusion (Ifos 9) in patients with ASTS.
Methods: Patients were strati￿ ed by histological subtype, grade,
metastatic site, performance status and institution. Response was
evaluated  after  each  2  cycles  and  all  responses  independently
reviewed. An interim analysis was carried out by an independent
data monitoring committee after four years.
Results: Between 1997 and  Sept  2001, 322/760 patients  were
recruited. Groups were evenly divided  by  strati￿ cation  factors.
Histological  types  were  leiomyosarcoma  31.4%, liposarcoma
12.1%, synovial sarcoma 9.3%, others 46.2%.Toxicity was worse
in both ifosfamide arms; grade 3 febrile neutropenia occurred in
8.3%  doxorubicin  patients, 20.7%  Ifos  3*3  and  17%  Ifos  9
patients. Response rates were: Doxorubicin 11% (CR 0.9%, PR
10.1%), Ifos 3*3 6.5% (CR 0.9%, PR 5.6%), Ifos 9 9.4% (CR
1.9%,PR 7.5%).With a median follow up of 14 months,there was
no signi￿ cant difference in progression free or overall survival in
the three arms.The study hypothesis of a difference of 10% in PFS
at 1 year was rejected and the trial stopped early on the advice of
an independent data monitoring committee.
Conclusions: For the majority of patients with ASTS for whom
single agent chemotherapy is appropriate, doxorubicin 75mg/m2
remains the treatment of choice.
Expression of the Ihh/pthrp and Bmp Receptors Has Diagnostic
Relevance in Cartilagineous Lesions
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Objectives: Indian  Hedgehog  (and  its  downstream  target)  and
Bone Morphogenic Proteins have shown to play a relevant and
independent role  in  chondrocyte  proliferations and  regulations
during embryonic development. Aim of this study is to evaluate if
the expression of these molecules can be used for diagnostic clas-
si￿ cation of cartilaginous lesions.
Methods: Cartilagineous  lesions  were  analysed  by  immuno-
histochemistry  with  the  antibodies  for Indian  Hedgehog  (Ihh),
Parathyroid  Hormone  related  peptide  (PTHrp), Bone
Morphogenic Protein Receptors type 1 A (BMPR-IA), type 1B
(BMPR-IB) and type 2 (BMPR-II) receptors. Staining was evalu-
ated by 4 investigators independently.
Results: We observed a  distinct pattern of expression of these
proteins  in  speci￿ c  subset  of  cartilagineous  lesions. Ihh  and
BMPR-II expression were found in 4,9% and 5,1% of osteochon-
dromas. In contrast, the same antigens were expressed in 54,1%
and 48,3% of peripheral chondrosarcomas. In central chondroid
lesions, two different proteins, PTHrp and BMPR-IB expression
showed different pattern in enchondromas (11,1% and 25%) and
grade I chondrosarcomas (67,7% and 79,5%).
Conclusions: Immunohistochemical  detection  of  these  proteins
could identify different subset of cartilagineous lesions and could
be useful for diagnostic purposes.
Dedifferentiated  Chondrosarcoma: Updated  Outcomes  With
Current Treatment  Approaches  As  Compared To Those  Prior 
To 1984
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Objectives: Dedifferentiated  chondrosarcoma  presents  a  very
dif￿ cult clinical problem. Long term survival is known to be poor,
but  a  large  clinical  series has  not  been analyzed  in  the  era of
modern diagnostic and treatment modalities.
Methods: A  retrospective chart  review  of  all  cases  of  patients
presenting with dedifferentiated chondrosarcoma at our institu-
tion from 1984–2000 was performed.This was done as an exten-
sion  to  a  study  published  in 1986 prior  to  the  era of  modern
chemotherapy.
Results: There were 42 cases in 25 men and 17 women of average
age 56 (range 24–83 years). MSTS grades at presentation were 5
IIA, 27 IIB, and 10 III.Three patients underwent biopsy only, 19
had limb sacri￿ cing, and 20 had limb sparing procedures; surgical
margins were intralesional in 3, marginal in 2, and wide in 20, and
radical in 14.Twenty-seven patients received adjuvant therapy (22
chemotherapy  only, 2  radiotherapy  only, 3  combined  therapy).
Median survival was 8 months; 5-year survival was 7.1%. There
was no statistical difference in survival between patients who did
and did not receive chemotherapy, had wide versus radical resec-
tion, or had limb sparing versus sacri￿ cing procedures.There were
no statistically signi￿ cant difference between patients treated prior
to 1986 and those subsequently.
Conclusions: Despite advances in diagnostic modalities, surgical
treatments, and adjuvant therapies, dedifferentiated chondrosar-
coma continues to carry a poor prognosis.The use of current adju-
vant  chemotherapy  and  its  inherent risks and bene￿ ts  remains
questionable in this population.
Desmoid Tumors. A Clinical Review Of 30 Patients With More
Than 20 Years Follow-up
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Objectives: Thirty patients with desmoid tumors treated at our
department with more than 20 years follow-up (mean 28 years)
were reviewed.
Methods: Twenty patients were women,10 were men with a mean
age of 39 years. The tumors were located in the abdominal wall
(7), upper extremity (6), lower extremity (6), back (5), thoracic
wall (4), head-and-neck region (1). One patient presented with
multifocal  tumors. Largest  mean  tumor  diameter  was  7  cm.
Twenty-nine patients had surgery,3 of which had additional radio-
therapy. One  patient  received  adjuvant  antioestrogen  therapy
(Tamoxifen®). The  surgical  margins  were  intralesional  in  6
tumors, marginal  in 13 tumors  and wide/compartmental in  10
tumors. One patient had radiotherapy alone.
Results: Two patients died of non-tumor related causes. Sixteen
patients were continuously disease free (CDF). At follow-up, all
patients but 1 were free of symptoms. Thirteen patients had no
evidence of disease (NED), two of which were primarily operated
with debulking surgery. Six patients had mild to moderate post-
treatment symptoms. One patient was alive with disease (AWD).
She was operated on three times and had additional radiotherapy
as  well  as  antioestrogen  therapy. At  follow-up  the  patient  had
disabling symptoms.The overall recurrence rate was 44%. A less
tendency for recurrence was evident in patients operated with a
wide or compartmental excision.Three tumors disappeared spon-
taneously.
Conclusions: Patients  operated  with  a  wide  or  compartmental
margin had the least risk to develop recurrent tumor. Observation
alone might be considered in selected cases.
Unexpected  Severe Toxicity  Of  Low  Dose  Methotrexate  And
Vinblastine In Patients With Desmoid Tumours
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Objectives: Evaluation of tolerability of low dose chemotherapy
for desmoid tumours.
Methods: 10  patients  with  desmoid  tumours  (six  male; four
female; median age 43 years [17–75], median WHO performance
score 0 [0–1]), for whom surgery was considered to be severely
mutilating, were treated with chemotherapy consisting of weekly
intravenous methotrexate 50 mg and vinblastine 10 mg, scheduled
to be given for one year.This regimen has previously been reported
as active for desmoids and to be devoid of serious toxicity.Toxicity
was assessed using NCI-CTC criteria. If full doses could not be
given because of side effects the dose was either reduced or the
dose interval was extended, based upon the observed type of toxi-
city. The  reasons  for preliminary  termination  of  the  treatment
regimen were registered.
Results: No patient could complete the treatment. In all cases
dose reduction, delay of dose interval or preliminary termination
of the treatment was necessary. All patients had nausea varying
from  grade  I-III, despite  antiemetics. Four  patients  developed
polyneuropathy (grade I-III), four had continuous fatigue (grade
I-II), two developed leucopenia (grade II-III), two patients devel-
oped grade II-III impairment of liver function. One patient devel-
oped  reversible methotrexate  induced  pulmonary  ￿ brosis. One
patient experienced a complete remission lasting 26 months,eight
had stable disease, and one progressed on treatment. Six patients
underwent surgery following chemotherapy.
Conclusions: Our experience indicates severe long term toxicity is
related  to  this  chemotherapy. This  is  in  sharp  contrast  with  a
previous report.We believe the regimen can not be recommended
for routine use outside study protocols.
Higher Postoperative Radiation Dose Improves The Local Control
Rate  For  Patients With  Positive  Surgical  Margins And  Locally
Recurrent Soft Tissue Sarcoma
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Objectives: To  evaluate  the  relationship  between  postoperative
external beam radiation dose and local control for patients with
risk factors for local recurrence after surgery and radiation.
Methods: From 1961 to 1999, 804 patients with non-metastatic
soft tissue sarcoma were treated with gross total surgical resection
and post-operative radiation, with or without adjuvant chemother-
apy. Histological  sub-type  was  as  follows: MFH, 265  patients;
liposarcoma,97;synovial sarcoma,91;unclassi￿ ed,90;neurogenic
sarcoma, 58; Rhabdomyosarcoma, 39; other, 164. Surgical resec-
tion  margins  were  positive  or  uncertain  in  377  patients. One
hundred  and  forty eight  patients  (18%)  presented with  locally
recurrent disease  after  previous  surgical  resection. Histological
grade was low/intermediate in 234 patients and high in the remain-
ing 570 patients. Median tumor size was 5cm (range 0.5–36cm).
Radiation was delivered to a median dose of 61Gy (range 36–75).
Only 11 patients received doses <50Gy.Adjuvant systemic therapy
was given to 215 patients.
Results: At a median follow-up of 12 years, 322 patients (40%)
developed disease relapse at any site.The 10-year actuarial overall
and disease-free survival rates were 61% and 58%, respectively.
The 10-year actuarial local, nodal and distant control rates were
79%,96%, and 70%,respectively. Multivariate analysis con￿ rmed
an  independent  association  between  positive  surgical  resection
margins  (p<0.001), age  >47 years (p=0.002), high  histological
grade (p=0.006), size >5cm (p=0.01), locally recurrent disease
(p<0.001), postoperative radiation dose <64Gy (p<0.001) and an
inferior 10-year local control rate. In three of these high-risk sub-
groups higher radiation dose postoperatively improved the 10-year
local  control  rate. For  patients  with  positive  surgical  resection
margins radiation dose ›64Gy resulted in a 10-year local control
rate of 75% compared to 55% for lesser doses (p<0.001). For
patients presenting with locally recurrent disease after previous
surgical treatment radiation doses ›64Gy resulted in a 10-year local
control rate of 76% compared to 59% for lesser doses (p=0.05).
For patients with high grade disease the same doses resulted in 10-
year local control rates of 79% as compared to 74%, however this
difference was of only borderline signi￿ cance (p=0.06).
Conclusions: This radiation dose-response analysis suggests that
the adverse prognostic signi￿ cance of positive surgical resection
margins and locally recurrent disease after surgical resection may
be partially overcome with postoperative radiation dose in excess
of 64Gy.
Advantages Of Proton Beams In Treatment Pelvic Sarcomas
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Objectives: To assess the clinical gains predicted by use of proton
beams rather than  the highest technology photon  beams in the
radiation treatment of sarcomas of the pelvis.
Methods: Complete treatment plans based on intensity modu-
lated proton  and  photon  methods for sarcomas at the sacrum,
pubic  bone/symphysis  and  inguinal  soft  tissues. The  treatment
plans are to account for heterogeneities in tissue densities, motion
of the target and critical normal tissues during and between treat-
ment  sessions. The  comparison  of  the  treatment plans  will  be
based upon calculated complication probabilities for the critical
normal tissues for the different plans. Estimates of the maximum
dose for each plan for a Grade IV complication probability of 1, 3
and 5% will be presented.Estimates will be presented of the tumor
control probability for each plan for the three levels of complica-
tion probability.
S70 CTOS abstractsResults: The major predicted clinical gains for each of the three
sites are: Site 1 sacrum, virtually no dose to the intestinal track;
Site 2 pubic bone/symphysis  – virtually no dose to the urinary
bladder and Site 3 inguinal regional, virtually no dose to femoral
head/neck. The result is marked reduction to treatment related
morbidity at those normal tissues.The markedly lower doses to the
intestinal tract and bladder will offer the addition gain of higher
chemotherapy  doses. The  ￿ nal  calculated  probabilities  will  be
presented in November.
Conclusions: For radiation treatment of sarcomas of these three
anatomic sites, proton  beam  technology  is predicted to  yield  a
higher proportion of patients who are rendered tumor and compli-
cation free.
Phase  2 Trial With  Imatinib  (glivec, Sti571)  In  Patients With
Gasto-intestinal Stromal Tumors (gist): Activity Results After 1
Year. A Study Of The EORTC Soft Tissue And Bone Sarcoma
Group (STBSG).
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Objectives: From  January  to  March  2002, the  STBSG  has
included 27 patients with GIST in a phase II trial of imatinib.
Methods: Patients were treated at a dose of 400 mg b.i.d. (the
maximum tolerated dose according to the results of the previous
STBSG phase I trial in soft tissue sarcoma).
Results: Median age  was  56 years (range: 30–75), 19 patients
were male (70%), performance status (WHO scale) was 0 in 12
cases (44%) and 1 in 15 cases. The reported disease origin was
gastro-intestinal in 17 patients (63%) and retro/intra-abdominal in
10 cases;14 patients (52%) had received prior chemotherapy.Side
effects have been reported elsewhere (ASCO 2002,abstract 1609).
One year after the end of accrual, 22 patients  were still under
protocol therapy. A total of 19 patients (70%) have responded to
therapy (1CR,18PR);2 of these patients progressed after 261 and
323 days of treatment respectively, but were kept on treatment.
Five patients had a stabilization of their disease, ongoing for 280,
371 and 391 days in 3 cases.The 3 other patients had progressive
disease at the ￿ rst disease evaluation (8 weeks).The 1-year esti-
mate  (Kaplan-Meier) of  progression  free survival  is  73% (s.e.:
9%). So far, 2 patients have died (both from progression).The 1-
year survival estimate is 96% (s.e.: 4%).
Conclusions: These results indicate that the activity of imatinib in
GIST is long lasting. STBSG has subsequently randomized 946
patients in a phase III trial to compare the activity of the drug
administered at 400mg/day and 400mg b.i.d.
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Molecular  Targeting  Of  Pdgfb  By  Imatinib  Mesylate  In
Dermato￿ brosarcoma Protuberans
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Objectives: Dermato￿ brosarcoma protuberans (DFSP) are highly
invasive dermal mesenchymal neoplasms that occasionally metas-
tasize. Standard chemotherapy has not been effective. Activation
of the platelet derived growth factor B (PDGFB) receptor,a trans-
membrane  kinase, by  aberrant  expression  of  platelet  derived
growth factor B is central to the pathogenesis of DFSP.We treated
a patient with unresectable, metastatic DFSP with imatinib mesy-
late to investigate the response of this malignancy to inhibition of
the PDGFB pathway.
Methods: A  patient  with  metastatic  DFSP  received  imatinib
mesylate twice daily.Tumor response to therapy was assessed using
￿ uorodeoxyglucose-positron emission tomography,magnetic reso-
nance imaging, immunohistochemistry and standard pathology.
Results: The patient tolerated twice daily ingestion of imatinib
mesylate.After two weeks of treatment,￿ uorodeoxyglucose uptake
in the DFSP fell to background levels.Tumor volume progressively
shrank over four months by more than 75% allowing for complete
resection of the  residual mass. Histologic evaluation revealed a
complete pathologic response to treatment.Adjuvant therapy with
imatinib mesylate was not used.The patient remains free of tumor
more than nine months after surgery.
Conclusions: Imatinib  mesylate  appears  to  be  highly  active  in
DFSP  when administered twice daily. The  optimal  duration  of
therapy to obtain a complete response is not known, but in this
patient,four months of treatment resulted in a complete histologic
response and allowed for complete resection of the residual mass.
This result demonstrates that therapies targeting speci￿ c oncogene
pathways central to the pathogenesis of a neoplasm can result in
dramatic therapeutic effects.
Gleevec Therapy  In  C-kit  Negative  Soft  Tissue  Sarcomas: A
Molecular Rationale.
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Objectives: Imatinib mesylate (Gleevec) therapy has revolution-
ized the treatment of c-KIT positive soft tissue sarcomas (STS)
such  as GIST. The North American branch  of the Connective
Tissue Oncology Society is currently conducting a phase II trial of
Gleevec in patients with advanced non-GIST STSs. Recently, a
patient with advanced Malignant Fibrous Histiocytoma (MFH)
responded dramatically to Gleevec therapy.Immunohistochemical
analysis of the resected tumor demonstrated the absence of c-KIT
and the presence of PDGFR a and its ligand PDGF-A.The phos-
phorylated form of AKT was also present. PDGFR a and b are
membrane  bound  receptor tyrosine  kinases  (RTK), which  are
thought to be alternate targets for the RTK inhibitor,Gleevec.The
genomic sequence for these RTKs share extensive homology with
both  c-KIT and c-ABL, especially in the region coding for the
ligand-binding domain. PDGFR a and b, c-KIT and c-ABL are
all strongly inhibited by Gleevec.AKT is a cytoplasmic serine/thre-
onine kinase, which is a common target for RTK phosphorylation.
It is involved in the regulation of cell survival.
Methods: In order to  further  determine  which  patients  would
bene￿ t  from  empirical  Gleevec  therapy, sections  of  a  tissue
microarray (TMA) with multiple cores from eight different STS
subtypes  (rhabdomyosarcoma  (n=15), leiomyosarcoma  (n=8),
liposarcoma (n=10), angiosarcoma  (n=8), MFH (n=16), GIST
(n=5), synovial sarcoma (n=12), and ￿ brosarcoma (n=11)) were
stained using routine immunohistochemical stains for PDGFR a
and b, c-KIT and AKT. Sections were also stained with antibodies
speci￿ c for the phosphorylated form of AKT.
Results: Analysis of the data indicates that although  PDGFR a
and  b  are  ubiquitous  in  distribution  amongst  STS, c-KIT
immunoreactivity was only observed in GISTs, synovial sarcomas
and angiosarcomas.AKT immunoreactivity was observed in 68 of
85 STS (80%). The phosphorylated  form of AKT was seen in
68%, ranging from 36% in ￿ brosarcomas to 87.5 % in MFH.
Conclusions: These  results  suggest  that  adjuvant  therapy  with
Gleevec is may be useful in c-KIT negative STSs, where activated
forms of AKT is present. The results also  provide a molecular
rationale for the dramatic response seen in the c-KIT negative
MFH patient undergoing therapy with Gleevec.
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Approach To Prosthetic Reconstruction In Sternal Sarcoma
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Objectives: We performed a retrospective analysis of our experi-
ence in chest wall reconstruction after sternectomy for high grade
sarcoma.In particular we evaluate a technique of prosthetic recon-
struction,where wide resections always including the chest wall are
mandatory.
Methods: Sternal and chest wall reconstruction were performed
in ￿ fteen patients (7 chondrosarcoma,2 osteosarcoma,1 angiosar-
coma, 1 Ewing’s sarcoma, 2 radiation-induced sarcoma, 1 liposar-
coma, 1 malignant  ￿ brous histiocytoma). After resection of the
primary  tumor, a  tailored  Marlex  mesh  was  anchored  to  the
margins of the wall defect. One or two mouldable metallic plates
were ￿ xed either to the remaining rib or to the clavicular stumps
and to the residual sternum supporting the mesh, avoiding chest
wall  volet. Pedicled  muscle  ￿ aps  were  always  associated  to
complete reconstruction.
Results: Perioperative mortality  was  6.6%  (1  case). The  mean
time of postoperative intubation was 8 hours (range 0–18).During
postoperative  chemotherapy  two  patients  presented  a  wound
infection, healed after local debridement.The margins achieved by
“en bloc” resection of the entire tumor (mean resected skin area
99.7cm2) was wide in 12 patients and marginal in 3 (Enneking’s
surgical  staging  system). At  a  mean  follow-up  of  26.7 months
(range 68–12) 13 patients were alive (11 continuously disease free,
two alive with distant metastases or local relapse); two patients
died. All patients recovered their normal lifestyle.
Conclusions: The authors  believe that  the  reconstruction tech-
nique adopted is feasible and favorable due to its short hospital-
ization, good  local  control, and  because  it  prevents  prolonged
post-operative  mechanical  ventilation  and  future  restriction-
related working incapacity.
Autobiological  Reconstruction  With  Preserved  Joint  Function
After Surgical Treatment Of Bone Sarcomas In Children
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Objectives: After  limb-salvage  surgery  in  young  children  with
bone sarcomas our preferences are biologic reconstructions using
autologous vascularized ￿ bula grafts.This report describes 3 chil-
dren in whom the joint function could be preserved in the knee,
hip and shoulder joints respectively.
Methods: All 3 patients had clinically good response to preoper-
ative chemotherapy.A 9-year-old girl with an osteosarcoma of the
distal femur was reconstructed with dual parallel ￿ bula grafts with
the proximal ￿ bula epiphysis towards the knee.The lateral collat-
eral ligaments (LCL) were sutured to the cruciate ligaments. Soft
tissue resection was kept to a minimum since it was a stage IIA
lesion.
A 9-year-old girl with a stage IIB Ewing sarcoma of the right prox-
imal femur was reconstructed with 2 ￿ bula grafts; one proximal
￿ bula  replaced  the  femoral  head  and  was  inserted  into  the
remaining femur, the other graft served as support.The hip-joint
capsule was sutured like a pouch around the ￿ bula head.
A 6-year-old girl with a stage IIB telangiectatic osteosarcoma of
the left proximal humerus was reconstructed with a single ￿ bula
graft.The origin of the long biceps tendon was sutured to the LCL,
and the rotator cuff was sutured as a pouch around the ￿ bula head.
Results: 19  months  postoperatively  the  knee  reconstruction is
ambulatory with a (MSTS) score of 10/30. At 33 months the hip
reconstruction is ambulatory with a score of 13/30.At 29 months
the shoulder reconstruction has an excellent function with a score
of 27/30.
Conclusions: Until now the follow-up results appear encouraging.
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Objectives: The  purpose  of  this  study  was  to  determine  the
outcome of patients after distal humerus reconstruction for bone
tumors using endoprosthetic replacement (EPR).
Methods: 10 patients were retrospectively reviewed after resection
of a primary or metastatic tumor of the distal humerus between
1970 and 2001.They all had a custom made distal humerus EPR.
No patients was lost to follow up.The Toronto Extremity Salvage
score (TESS) was used to assess function in patients still alive.
Results: There  were 4  male  and  6  female  patients, with  ages
ranging from 15 to 76 years.The period of follow up ranged from
5 months to 31 years. 8 patients had primary tumors and 2 had
secondary tumors. 4 out of 10 patients developed metastasis and
died 12 to 71 months after the operation. None of the 10 patients
had local recurrence, infection, amputation or permanent nerve
palsy. Average  ￿ exion  deformity  was  15  degrees  (0–35)  and
average ￿ exion of these patients was 115 degrees (110 – 135).
There were 3 revisions at 48, 56 and 366 months for aseptic loos-
ening.There were 3 rebushings of the plastic inserts at 62,78 and
113 months.Two of the three rebushings were done after revision
of  the  humeral  component  at  6  months  and  30  months. The
average TESS score for these patients was 72.91 (29.2 to 93.33).
Conclusions: Custom made EPR for distal humeral tumors are an
effective way of replacing the diseased bone leading to a reason-
able level of function and an acceptable failure rate.
Survivorship Analysis Of 141 Modular Metallic Endoprostheses
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Objectives: To evaluate the survival rates and clinical results of
modular endoprostheses in patients who have had resections for
musculoskeletal tumors and some non-tumorous conditions.
Methods: We retrospectively reviewed the records of 141 patients
in whom a modular endoprosthesis was implanted over the past 8
years. Statistical data was compiled using Kaplan-Meier survival
analysis and a multivariate regression analysis was performed to
identify independent risk factors. Failure was de￿ ned as need for
revision of the majority of the prosthetic components or complete
removal of the implant. Clinical results were graded according to
a scoring system previously reported.
Results: There were 67 males and 74 females.The average age at
the time of surgery was 48.9 years.There were 13 failures yielding
an overall implant survival of 91%. Based on Kaplan-Meier esti-
mates, the endoprosthetic survival rate was 88% at 3 years and
76% at 5 years; per location, it was 100% for proximal humerus,
100% for proximal femur, 87% for modular knees, and 53% for
total femoral implants at 3 years (p = 0.03). The failure rate of
failed allografts converted to an endoprosthesis was 18% versus
6% for primary endoprostheses (p = 0.08). However, multivariate
analysis showed that only location, infection, and loosening were
independent risk factors for prosthesis failure. Clinical scores were
74% good-excellent and 26% fair-poor. Ten patients died (9 of
metastatic disease, 1 from peri-operative complications).
Conclusions: We feel that our experience, albeit short in follow-
up, is similar to other endoprosthesis survivorship reports in the
literature at early time points.
Low  Complication  Rate  With  Limb-sparing  Resection  And
Endoprosthetic Reconstruction: Survival Analysis Of 251 Patients
And Analysis Of 20-year Experience
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Objectives: In order to  evaluate  patterns  of  complications  and
prosthetic survival after endoprosthetic reconstruction for bone
tumors, the authors reviewed all procedures performed over a 20-
year period at a single institution.
Methods: Methods
Patients who underwent one or more procedures with a segmental
endoprosthesis, except  for  saddle  prostheses, are  reported.
Prosthetic failure is de￿ ned as removal of a cemented component.
Kaplan-Meier survival analysis, interval to complication and the
number of operations per patient are calculated.
Results: Results
A total of 251 patients underwent surgery. Of these, 197 patients
(78%) underwent only one surgery.The remaining 54 underwent
a mean of 3.5 procedures.
Complication
Type n Follow-up
(months) Interval between ￿ rst and second surgery # Surgeries
Prosthesis failure
mechanical 20 121.2 45.5 3.6 11 (7 custom)
soft tissue
(super￿ cial) 10 35.1 44.1 3.0 0
soft tissue
(deep) 5 76.6 44.1 3.0 0
infection 11 79.3 14.2 4.6 6
dislocation 2 29.8 7.8 3.0 0
other 6 81.3 7.8 3.0 1
Overall 54 85.4 25.5 3.5 18
% (÷251) 21.5% 7.2%
CTOS abstracts S73Conclusions: Overall prosthetic survival (92.8%) has proven to be
greater than most surgeons anticipated in the early days of limb-
salvage surgery. At an average follow-up of 7 years, 67% (36/54)
patients who required reoperation were able to retain their pros-
theses. All patients with soft tissue complications were salvaged
with an average of 3 procedures,while 45% (5/11) of patients with
deep infections were salvaged. Prosthetic failure due to mechan-
ical  complications  diminished  signi￿ cantly from  64% (7/11) to
36%  (4/11)  with  introduction  in  1988  of  modular  prostheses.
Meticulous attention to technique and aggressive management of
soft-tissue complications leads to excellent prosthetic survival.
Is There A Case For A Randomized Clinical Trial For Treatment
Of Giant Cell Tumours?
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Objectives: The role of adjuvants in preventing local recurrence
following curettage of giant cell tumour of bone (GCT) remains
controversial.We have reviewed our experience of curettage alone
to fuel the debate.
Methods: All  patients  treated  for  primary  giant  cell  tumours 
of bone over a 27 year period by detailed curettage with a high
speed burr were reviewed. Risk factors for local recurrence were
identi￿ ed.
Results: Of 137 with previously untreated GCT of bone, 29 had
a pathological fracture. Campanacci grading showed that 14 were
grade I, 47 were grade II and 52 were grade III Following curet-
tage,26 patients (19%) developed local recurrence (LR) at a mean
of 22 months. Size, site and fracture were not related to LR. For
intraosseous tumours (grades I and II) the LR rate was 7% whilst
for extraosseous tumours the LR rate was 29%. Of the 26 LRs, 16
had a further curettage of whom 10 were cured by one curettage
and 4 following a third curettage.The success rate of curettage was
81% with one operation, 88% with two and 91% with three curet-
tages.The mean MSTS functional score in these patients was 94%.
Conclusions: The literature suggests an  overall LR  of  27% for
curettage and 19% when an adjuvant is used.With cryotherapy an
LR of 4% was achieved. Local control of GCT of bone is not yet
resolved. The  role  of  adjuvants  has  not  been  proved  by  the
published literature and an international prospective randomized
trial is recommended.
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Anatomic location vs. Prosthetic Types:
D. Femur P.Tibia P. Humerus P. Femur Scapula T. Femur Other Total
Custom 19 9 6 9 11 9 4 78
Modular 74 31 32 24 0 7 5 173
Expandable 0 0 0 0 0 0 0 11
Total 93 40 38 33 11 16 9 251